Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses the merger of Daiichi and Sankyo, how the combined entity has evolved, and how the firm's Benicar/amlodipine combination Azor figures as a key growth driver going forward.
You may also be interested in...
Daiichi Sankyo Gains Diabetes Indication For Cholesterol Drug WelChol
Therapy indicated as adjunctive treatment to improve glycemic control in type 2 diabetes patients.
Daiichi Sankyo Gains Diabetes Indication For Cholesterol Drug WelChol
Therapy indicated as adjunctive treatment to improve glycemic control in type 2 diabetes patients.
Daiichi Sankyo/Forest’s Hypertension Therapy Azor Gets FDA Nod
Azor will compete against Novartis’ recently approved Exforge.